Tiako Meyo Manuela, Chen Jeanne, Goldwasser Francois, Hirsch Laure, Huillard Olivier
Department of Medical Oncology, Institut du Cancer Paris CARPEM, AP-HP, APHP.Centre, Hôpital Cochin, Paris, France.
Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), AP-HP, APHP.Centre, Hôpital Cochin, Paris, France.
Ther Clin Risk Manag. 2022 Jul 8;18:683-698. doi: 10.2147/TCRM.S263832. eCollection 2022.
Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent of immune checkpoint inhibitors (ICI) or VEGFR TKI plus ICI combinations. This article focuses on the profile of one of these ICI plus VEGFR TKI combination, avelumab plus axitinib. We detail the characteristics of each drug separately, and then we explore the rationale for their association, its efficacy and the resulting toxicity. Finally, we examine the factors associated with avelumab plus axitinib outcomes, and their impact on therapeutic strategy.
直到最近，转移性肾细胞癌（mRCC）的获批一线治疗方案还是由靶向血管内皮生长因子受体（VEGFR）的酪氨酸激酶抑制剂（TKI）单药治疗组成。在过去几年中，随着免疫检查点抑制剂（ICI）或VEGFR TKI加ICI联合方案的出现，一线治疗格局发生了改变。本文重点介绍其中一种ICI加VEGFR TKI联合方案——阿维鲁单抗加阿昔替尼的情况。我们分别详细阐述每种药物的特性，然后探讨它们联合使用的理论依据、疗效及由此产生的毒性。最后，我们研究与阿维鲁单抗加阿昔替尼治疗结果相关的因素及其对治疗策略的影响。
